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Abstract
Background/Objective: While several prognostic factors have been identified in breast carcinoma, the clinical
outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide
difficult treatment decisions. Axillary lymph node metastasis (ALNM) is one of the most important prognostic
determinants in breast carcinoma; however, the reasons why tumors vary in their capability to result in axillary
metastasis remain unclear. Identifying breast carcinoma patients at risk for ALNM would improve treatment
planning. This study aimed to identify the factors associated with ALNM in breast carcinoma, with particular
emphasis on basal-like phenotype.
Methods: Breast carcinoma patients (n = 210) who underwent breast conserving surgery and axillary lymph node
dissection (ALND) (level I and II) or modified radical mastectomy were included in this study. Pathological and
immunohistochemical data including individual receptor/gene status was collected for analysis. The basal
phenotype status was ascertained using the basal cytokeratin markers CK5, CK14, CK17 and EGFR.
Results: ALNM was found in 55% (n = 116) of the patients. On univariate analysis, multicentric disease, large tumor
size (>2 cm), vascular and lymphatic invasion, epithelial hyperplasia, necrosis, in situ carcinoma and perineural
invasion were associated with higher risk for ALNM, whereas CK5, CK14, EGFR positivity and basal-like tumor type
were associated with lower risk. On multivariate analysis, CK5 positivity (OR 0.003, 95%CI 0.000-0.23, p = 0.009) and
lymphatic/vascular invasion (OR 17.94, 95%CI 4.78-67.30, p < 0.001) were found to be independent predictors.
Conclusions: Although the value of complete ALND has been questioned in invasive breast cancer patients,
treatment decisions for breast carcinoma have been influenced by many parameters, including lymph node status.
Since histopathologic characteristics and expression of biological markers varies among the same histologic
subtypes of breast carcinoma, specific clinical and histopathologic features of the primary tumor and ALN status
like sentinel node might be used to tailor the loco-regional and systemic treatment in different clinical settings.
Background
Although breast cancer represents a major cause of
morbidity and mortality, early detection and the use of
aggressive multimodal treatment have successfully
resulted in a decrease in the mortality due to this dis-
ease [1-3]. Currently, the most important prognostic fac-
tors are nodal status, tumor size, hormone receptor
(HR) status, and histological grade, although numerous
other clinicopathological factors and novel molecular
markers have been investigated to improve the
prediction of clinical outcome [4,5]. An ongoing chal-
lenge is to find improved methods of identifying and
classifying groups of tumours with differing biological
behaviors or responsiveness to specific therapies. Recent
studies using gene expression profiling and immunohis-
tochemistry have identified a distinct subset of breast
tumours that exhibit a basal phenotype or express a
gene expression signature that includes a relatively high-
level expression of stratified epithelial/basal cytokeratins
(CK5, CK14 and CK17) [6-12]. Triple negative (TN)
breast cancers are defined as the absence of estrogen
receptor (ER), progesterone receptor (PR) and HER2
expression, accounting for 10-17% of all breast
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ER and PR positivity and the methods for HER2 assess-
ment [13,14]. Expression of basal markers identifies a
biologically and clinically distinct subgroup of TN
tumors defined as basal-like breast cancer (BLBC). TN
cancer and BLBC are associated with poor outcome and
lack the benefit of targeted systemic therapy. The prog-
nostic value of TN and BLBC is of paramount impor-
tance. The significance of BLBC stems not only from its
poor prognostic feature but also from its distinct mole-
cular and biological characteristics. These distinct char-
acteristics have led to increased interest in BLBCs in an
attempt to identify better systemic therapy regimens and
novel therapeutic targets for these aggressive tumors. A
multivariate analysis has shown the effect of the basal
cell phenotype upon prognosis to be independent of
other known prognostic factors, including tumour size,
grade and lymph node status [8]. Several studies have
shown that basal cytokeratins were associated with
shorter survival in the lymph node (LN) negative
tumours but not in the LN positive group [15,16]. In
contrast, other studies showed an association between
basal CK expression and survival in the LN positive
group, but not in the LN negative group [9,17].
Axillary lymph node dissection (ALND) has been the
standard of care in patients with invasive breast cancer
in order to identify those with lymph node metastases,
and hence estimate prognosis and guide the selection
of patients for adjuvant therapy. Although no definitive
evidence exists as to the therapeutic role of ALND, it
is universally acknowledged that staging the axilla is
mandatory for planning the proper treatment of
patients with invasive breast cancer [18,19]. However,
ALND has been shown to be associated with complica-
tions such as pain, lymphedema and shoulder stiffness
[20]. Although it has some limitations, sentinel lymph
node biopsy (SLNB) reduces the incidence of such
complications and it is not associated with an
increased risk of regional tumor recurrence [21]. If the
axillary lymph node status could be accurately pre-
dicted prior to surgery, then selected patients who
have an acceptably low probability of axillary lymph
node metastasis (ALNM) might avoid a full ALND and
its associated morbidity.
The purpose of this study was to estimate the likeli-
hood of axillary lymph node involvement based on a
variety of clinical and pathologic factors including basal
phenotype in breast carcinoma patients and identify pre-
dictors for axillary lymph node involvement. Accurate
prediction of the axillary nodal status and identifying
the subgroup of basal phenotype will help optimize
patient care through better planning of surgical treat-
ment, radiotherapy and chemotherapy.
Methods
Patients and collection of data
This study included 210 breast carcinoma patients who
underwent breast conserving surgery and ALND (level I
and II) or modified radical mastectomy (MRM) in Fatih
University Hospital between March 2004 and August
2010. None of the patients had distant metastasis. Medi-
cal records of the patients were reviewed to collect his-
topathological and immunohistochemical data including
age, presence of axillary lymph node metastasis, tumor
size, laterality of the tumor (unilateral or bilateral), mul-
ticentricity, estrogen receptor (ER), progesterone recep-
tor (PR) and human epidermal growth factor receptor 2
(HER2) status. Tumour stage was determined according
to the criteria established by the 7th edition of Ameri-
can Joint Committee on Cancer in Cancer Staging Man-
ual [22]. Histological grade was determined according to
the Elston and Ellis modification of the Scarff-Bloom-
Richardson grading system [23]. The ALND specimens
were examined according to local protocol where lymph
nodes are identified without clearance of the fat and
each node is bivalved and embedded in paraffin. At least
one section of each node stained with haematoxylin and
eosin (H&E) was examined, but immunohistochemistry
was not used routinely to evaluate these nodal sections.
For the purpose of this study, archival hematoxylin and
eosin (H&E)-stained slides of cases were independently
re-evaluated by three of the authors for histological typ-
ing, tumor grading, and presence of microcalcification,
in situ carcinoma, perineural invasion, necrosis and
epithelial hyperplasia. Multicentricity and multifocality
were defined as the presence of tumor in multiple quad-
rants or the discontinuous growth of tumor in the same
quadrant, respectively. An extensive intraductal compo-
nent (EIC) was defined as the presence of intraductal
carcinoma both in the invasive tumor and in adjacent
breast tissue that comprised >25% of the tumor. In addi-
tion, representative blocks were chosen and screened for
the expression of P53, EGFR, CK5, CK14, CK17 and
Ki67.
Immunohistochemical examination
Routinely processed, formalin-fixed, parafin-embedded
tissue sections of 4 μm thickness were cut and mounted
on polylysine-coated slides. Immunohistochemical analy-
sis was carried out as described previously, with antibo-
dies against ER, PR, HER2, CK5, CK14, CK17, p53,
Ki67, and EGFR [24]. The primary antibodies for HER2,
K i 6 7 ,C K 1 7 ,E G F R ,P 5 3a n dp r o g e s t e r o nr e c e p t o rw e r e
supplied by Dako Corporation (Glotsrup, Denmark). All
other three markers were studied using primary antibo-
dies supplied by Thermo Fisher Scientific (Fremont, CA,
USA). The dilution factors were as follows: ER (clone
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1:200; p53 (clone DO-7), 1/50; Ki-67 (clone MIB-1),
1:150; and EGFR (clone H11), 1:50, cytokeratin 5 (clone
XM26) RTU, cytokeratin 14 (clone LL002) 1:100, cyto-
keratin 17 (clone E3) 1:30). All primary antibodies were
mouse monoclonal antibodies. Biotinylated anti-mouse
antibody was used as a secondary antibody and strepta-
vidin horseradish peroxidase (Zymed laboratories, San
Francisco, CA) methods were used according to the
instructions provided by the manufacturer. Slides were
counterstained with Harris hematoxylin. Positive and
negative controls for each marker were used according
to the supplier’s data sheet.
Immunohistochemical results were assessed by at least
two pathologists and scored semiquantitatively. ER and
PR positivity was defined as the presence of 10% or
more positively stained nuclei in ten high-power fields
[25]. A positive HER2 was recorded only if immunos-
taining was seen 3+ strong membranous staining
[26,27]. Positivity for CK5, CK14 and CK17 was defined
as the detection of at least 1% of invasive tumor cells
showing strong cytoplasmic and membranous staining
[9,27]. Immunostaining for EGFR was interpreted as
positive when at least 10% of tumor cells showed posi-
tive strong membranous staining. P53 immunostaining
was interpreted as positive when more than 10% of
tumor cells exhibited strong nuclear staining, and Ki-67
expression was considered low when <20% of cells were
stained. Tumors were classified as follows: luminal A
(ER+ or PR+ and HER2-), luminal B (ER+ or PR+ and
HER2+), HER2 (ER- and PR- and HER2+). A tumor was
defined as triple-negative when it is negative for all
three of the ER, PR receptors and HER2 and a triple-
negative tumor is defined as basal-like when it is posi-
tive for at least one of CK5, CK14, CK17 or EGFR.
Statistical analysis
Statistical Package for Social Sciences (SPSS) version 15
was used for the analysis of data. Categorical data are
presented as frequency (percentage) and continuous data
are presented as mean ± standard deviation. For the com-
parison of categorical data, Chi-square test or Fisher’s
exact test was done, and continuous variables were com-
pared using unpaired t-test. In order to identify the inde-
pendent predictors of axillary lymph node metastasis,
logistic regression was used. Odds ratios of the significant
predictors are provided along with 95% confidence inter-
vals (CI). Patients with missing data were excluded from
corresponding analyses. A p value < 0.05 was considered
as an indication of statistical significance.
Results
Patient and tumor characteristics stratified by ALNM
status are presented in Table 1. The mean age of the
patients was 53.5 ± 13.0 y (median: 52 y, range: 19-85
y). Fourteen patients were below age 35 y, 75 between
35-50 y and 121 patients were older than 50 y. Distribu-
tion of the tumors with regard to size was as follows: 9
(4.3%), pT1a; 23 (11%), pT1b; 54 (26%), pT1c; 99 (47%),







(n = 94) (n = 116)






≤49 79 31 (33.0%) 48 (41.4%) 0.211
≥50 131 63 (67.0%) 68 (58.6%)
Tumor size (mm)
Tmicro 3 3 (3.2%) 0 0.001
T1a 6 3 (3.2%) 3 (2.6%)
T1b 23 13 (14.0%) 10 (8.7%)
T1c 54 33 (35.5%) 21 (18.3%)
T2 99 37 (39.8%) 62 (53.9%)
T3 13 4 (4.3%) 9 (7.8%)
T4 10 0 10 (8.7%
Histologic grade
1 43 19 (20.2%) 24 (20.7%) 0.091
2 69 37 (39.4%) 32 (27.6%)
3 86 31 (33.0%) 55 (47.4%)
Unknown 12 7 (7.4%) 5 (4.3%)
Lymphovascular
invasion
Negative 100 75 (79.8%) 25 (21.6%) <0.001
Positive 105 16 (17.0%) 89 (76.7%)
Unknown 5 3 (3.2%) 2 (1.7%)
Perineural invasion
Negative 133 69 (73.4%) 64 (55.2%) 0.003
Positive 72 22 (23.4%) 50 (43.1%)
Unknown 5 3 (3.2%) 2 (1.7%)
Multicentricity
Negative 153 75 (79.8%) 78 (67.2%) 0.300
Positive 56 18 (19.1%) 38 (32.8%)
Unknown 1 1 (1.1%) 0
In situ carcinoma
Negative 46 29 (30.9%) 17 (14.7%) 0.005
Positive 159 63 (67.0%) 96 (82.8%)
Unknown 5 2 (2.1%) 3 (2.5%)
Microcalcification
Negative 136 66 (70.2%) 70 (60.3%) 0.087
Positive 67 24 (25.5%) 43 (37.1%)
Unknown 7 4 (4.3%) 3 (2.6%)
Epithelial hyperplasia
Negative 104 57 (60.6%) 47 (40.5%) 0.002
Positive 96 32 (34.0%) 64 (55.2%)
Unknown 10 5 (5.4%) 5 (4.3%)
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node metastasis was found in 55% (n = 116) of the
study group. Data on sentinel lymph node were available
in 31.5% (n = 66) of patients and 14.8% (n = 31) was
positive. In the remaining patients, sentinel lymph node
was not specifically assessed, although lymph node dis-
section was performed. The sentinel lymph node status
correctly predicted the status of the axilla in 97% of the
cases (64/66). The sentinel-node status was positive in
31 cases (47%), and negative in the remaining 35 cases
(53%). One of the 35 cases with a negative sentinel-node
status had non-sentinel node involvement. Among the
144 patients in whom sentinel node status was not
assessed, 60 (42%) did not have axillary lymph node
involvement and remaining 84 cases (58%) had ALNM.
Patients with or without SLN assessment did not differ
with regard to the frequency of ALNM: 42% (32/66)
versus 58% (84/44), p = 0.182. The mean number of
reactive lymph nodes was 17.2 ± 9.5 (median: 17, range:
0-46) in the whole study group and the mean number
of metastatic lymph nodes was 6.0 ± 6.8 (median: 4,
range: 0-39) in patients with ALNM.
Univariate analysis for relationship between the clini-
cal and pathological variables and the ALNM status is
presented in Table 2. Age, tumor size, multicentric dis-
ease, lymphovascular invasion, epithelial hyperplasia,
necrosis, in situ carcinoma and perineural invasion were
found to be significantly associated with ALNM. The
mean age of the patients with ALNM was significantly
lower indicating an increased risk for young patients.
Multicentric disease, large tumor size (>2 cm), lympho-
vascular invasion, epithelial hyperplasia, necrosis, exten-
sive in situ carcinoma and perineural invasion were
significantly more common among patients positive for
ALNM; thus associated with higher risk. Patients with
ALNM had similar distribution pattern for histological
type (p = 0.169) and tumor grade (p = 0.091). Poorer
histologic grade was associated with ALNM but the
relationship was not significant.
Table 3 shows the univariate analysis results for
immunohistochemical findings. A positive HER2 status
was not related to positive ALN status. In addition, ER
and PR expression did not predict the ALN status. The
distribution of tumors by ER/PR/HER2 status was simi-
lar among the groups with and without ALNM (p =
0.781). To investigate the relationship between molecu-
lar subtype and ALNM status, we used immunohisto-
chemical markers that have been previously compared
with gene expression profiles as surrogates and present-
ing characteristics of breast carcinoma [28]. Although
triple negative subgroup was not associated with
increased risk for ALNM, basal phenotype showed a
stronger association with negative ALN tumors (75%).
Among individual immunohistochemical parameters,
CK5, CK14, and EGFR positivity was associated with
lower risk for ALNM, whereas groups did not differ
with regard to the positivity of other individual molecu-
lar parameters. The frequencies of triple negative
tumors were also similar in the two groups; however,
basal-like tumors were more frequent among patients
with ALNM negative.
An additional multivariate logistic regression analysis
was conducted including the variables that were found
to have a significant association in univariate analysis
and their associations with ALNM status are presented
in Table 4. Only CK5 positivity, lymphovascular invasion
and age were emerged as independent predictors for
ALNM. CK5 positivity was associated with a lower risk
(adjusted OR 0.003, 95%CI 0.000-0.23, p < 0.009) and
lymphatic/vascular invasion (LVI) was associated with a
higher risk (adjusted OR 17.94, 95%CI 4.78-67.30, p <
0.001) for ALNM. Although marginal, age also emerged
as a significant predictor, with increasing age associated
with a lower risk (adjusted OR 0.95, 95%CI 0.91-1.00, p
< 0.049).
When patients having the two significantly favorable
parameters were specifically analyzed, i.e, patients with
CK5 expression and without lymphovascular invasion,
15 patients were identified. None of these patients had
ALNM.
Discussion
A common first route of spread for breast carcinoma is
through the axillary lymph nodes, and the incidence of
ALNM increases with larger tumors. Nodal status is the
most powerful independent prognostic factor in breast
cancer and remains the most important feature for
defining risk category. There is evidence that overall
survival decreases as the number of positive node
increases [4,29]. According to St. Gallen experts, invol-
vement of four or more nodes in the axilla by itself indi-
cated high-risk, but patients with one to three nodes
involved required HER2/neu overexpression or amplifi-
cation to be included in the high-risk group, with other
patients with one to three nodes included in the inter-
mediate-risk category [30]. Attempts have been made to
identify factors that may predict an increase risk of
nodal involvement in this group of patients. Although
nodal micrometastases were prognostically relevant in
several studies [31,32], neither they nor isolated tumor
cells in lymph nodes are considered in risk allocation.
Increasing size of the tumor has been found to be pre-
dictive of ALNM. Even patients with T1a and T1b dis-
ease have significant nodal involvement (5-15%) [33-36].
This study found a 29% overall incidence of ALNM in
patients with tumors ≤20 mm. There was no difference
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Age (yr), mean ± SD - 55.8 ± 12.4 51.7 ± 13.3 0.020
Age groups (yr)
<50 0.70 (0.40-1.23) 31/94 (33.0%) 48/116 (41.4%)
≥50 63/94 (67.0%) 68/116 (58.6%) 02.12
Tumor size (mm)
T1a (0-5.0) Reference 6/93 (6.5%) 3/115 (2.6%) 0.001
T1b (5.1-10) 1.54 (0.31-7.72) 13/93 (14.0%) 10/115 (8.7%)
T1c (10.1-20.0) 1.27 (0.29-5.65) 33/93 (35.5%) 21/115 (18.3%)
T2 (20.1-50.0) 3.35 (0.79-14.21) 37/93 (39.8%) 62/115 (53.9%)
T3-T4 > 50 9.50 (1.65-55.0) 4/93 (4.3%) 19/115 (16.5%)
Tumor size >20 mm 3.02 (1.70-5.36) 41/93 (44.1%) 81/115 (70.4%) <0.001
Histologic grade
1 Reference 19/87 (21.8%) 24/111 (21.6%)
2 0.68 (0.32-1.47) 37/87 (42.5%) 32/111 (28.8%) 0.332
3 1.40 (0.67-2.96) 31/87 (35.6%) 55/111 (49.5% 0.371
Bilateral disease 1.03 (0.37-2.88) 7/92 (7.6%) 9/115 (7.8%) 0.954
Multicentric disease 2.03 (1.07-3.87) 18/93 (19.4%) 38/116 (32.8%) 0.030
Lymphovascular invasion 16.69 (8.30-33.56) 16/91 (17.6%) 89/114 (78.1%) <0.001
Microcalcification 1.69 (0.93-3.08) 24/90 (26.7%) 43/113 (38.1%) 0.087
Epithelial hyperplasia 2.43 (1.37-4.31) 32/89 (36.0%) 64/111 (57.7%) 0.002
Necrosis 2.12 (1.10-4.08) 17/89 (19.1%) 38/114 (33.3%) 0.024
In situ carcinoma 2.60 (1.32-5.12) 63/92 (68.5%) 96/113 (85.0%) 0.005
Perineural invasion 3.02 (1.70-5.36) 22/91 (24.2%) 50/114 (43.9%) 0.003
Unless otherwise stated, data are expressed as n (%). SD, standard deviation; ALNM, axillary lymph node metastasis
Table 3 Univariate analysis of immunohistochemical findings and their association with axillary lymph node
metastasis







ER 1.14 (0.62-2.07) 63/92 (68.5%) 79/111 (71.2%) 0.677
PR 1.13 (0.62-2.07) 64/92 (69.6%) 80/111 (72.1%) 0.695
HER2 1.28 (0.64-2.56) 17/92 (18.5%) 25/111 (22.5%) 0.479
CK5 0.25 (0.10-0.61) 21/86 (24.4%) 7/95 (7.4%) 0.002
CK14 0.28 (0.09-0.91) 12/73 (16.4%) 4/77 (5.2%) 0.034
CK17 0.38 (0.09-1.52) 7/72 (9.7%) 3/77 (3.9%) 0.198
P53 0.95 (0.48-1.88) 23/71 (32.4%) 25/80 (31.3%) 0.880
Ki67 1.51 (0.80-2.82) 33/78 (42.3) 42/80 (52.5%) 0.200
EGFR 0.35 (0.15-0.82) 20/61 (32.8%) 10/69 (14.5%) 0.013
ER/PR/HER2 profile
ER/PR+, HER2- Reference 59/92 (64.1%) 71/111 (64.0%)
ER/PR+, HER2+ 1.50 (0.48-4.70) 5/92 (5.4%) 9/111 (8.1%) 0.488
ER/PR-, HER2+ 1.11 (0.49-2.53) 12/92 (13.0%) 16/111 (14.4%) 0.806
ER/PR-, HER2- 0.78 (0.36-1.71) 16/92 (17.4%) 15/111 (13.5%) 0.532
Triple-negative tumor 0.74 (0.35-1.60) 16/92 (17.4%) 15/111 (13.5%) 0.445
Basal-like tumor 0.25 (0.08-0.80) 12/92 (13.0%) 4/111 (3.6%) 0.017
Unless otherwise stated, data are expressed as n (%).ALNM, axillary lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human
epidermal growth factor receptor 2; CK, cytokeratin
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ferent histologic types.
Multicentricity has been evaluated as a potential pre-
dictive factor of ALNM. When a combined diameter
assessment was used, the frequency of lymph node posi-
tivity was not significantly different in multifocal versus
unifocal cases [37,38]. However, multicentric and multi-
focal breast cancer is associated with increased nodal
involvement compared to similar unifocal disease and
the tendency of breast tumors to metastasize is a reflec-
tion of the total tumor load [38]. Classification of
patients with breast cancer based on the size of the
dominant lesion, without taking into account multicen-
tricity, may not accurately reflect the risk of ALNM in
patients with small, screen-detected cancers. This may,
in turn lead to over- or under-treatment of some of
these patients. Univariate analysis of this study identified
multicentricity as a significant factor for ALNM. The
number of foci should be considered as an independent
prognostic parameter, which is currently not reflected in
the TNM classification. Therefore, cases with multi-
centric tumours should be analyzed separately and
should be included in the risk assessment by re-evaluat-
ing the current TNM classification.
In univariate analysis, there was a positive relation
between nodal involvement and EIC. It is possible that
EIC sometimes was associated with unrecognized multi-
focality of infiltrating cancer predisposing to nodal
spread. Further research is required to explore this and
other possible explanations.
Lymphovascular invasion has been proved to be the
strongest independent predictor of nodal involvement in
two series, and the grading system for lymph-vessel
tumor embolus is a very useful histological grading
system for accurately predicting lymph node metastasis
by IDCs [39,40]. In this study, both univariate and mul-
tivariate analysis identified lymphovascular invasion as
significant predictors for ALN involvement.
Despite controversial data available on the value of age
as a prognostic factor, the prognosis of breast cancer in
very young women is generally considered to be unfa-
vorable. Age has been found to be an independent prog-
nostic factor in the multivariate analysis with women
aged 35 years or younger having a shorter loco-regional
recurrence-free distant relapse and shorter overall survi-
val. When the data was matched for stage and lymph
node status, patients ≤35 years of age continued to
s h o wap o o r e r1 0 - y e a rd i s t a n tr e l a p s ef r e es u r v i v a l[ 4 1 ] .
Ten-year disease free survival (DFS) and overall survival
were worse in younger than in older (≥35 years)
patients. Of interest, younger patients with ER positive
tumors had a poorer DFS than patients with ER negative
tumors. In contrast, among older patients the DFS was
similar irrespective of ER status. Saghir et al. showed
that young age had a negative impact on the survival of
patients with positive axillary lymph nodes and positive
hormonal receptors [42]. According to Colleoni and col-
leagues, compared with less young, very young patients
with endocrine responsive and node-negative breast can-
cer have a worse prognosis [43]. Young patients tend to
have larger tumor sizes, more positive lymph nodes,
more negative hormone receptors, higher tumor grades
than their older counterparts [4,11,14,18,26,29]. The
issue remains controversial and not all studies reported
age as an adverse prognostic factor [18-21,26,27,29]. In
line with these findings, although the significance is
marginal, this study identified young age as a significant
predictor of ALNM. This negative predictive effect of
age on nodal involvement is consistent with earlier evi-
dence and indicates that breast tumours can be more
aggressive in younger women [44-46]. Alternatively, this
m a yb ed u et ot h el o n g e rp e r i o do fe x p o s u r et ot h e
screening service of older women, when compared to
the younger women; thus reflecting a cumulative protec-
tive effect of repeated screening.
The potential poor survival or early recurrence asso-
ciated with CK5/6 and CK17 expression in tumor cells
was first reported by Dairkee et al. in 1987 [47].
Although IHC-based assays do not provide so much
biological insight into tumor biology as mRNA-based
assays that include thousands of genes, this IHC assay
allowed classification of tumors into categories based on
the associations between intrinsic subtypes and prolif-
eration rates, overall survival, TP53 status, and BRCA1
mutation status [8-10,15,48]. In order to facilitate the
investigation of the ALNM frequencies in basal-like
breast cancer subtype, this study used a refined an IHC-
based assay. Basal markers are not routinely used in the
Table 4 Multivariate analysis of factors with significant
association with axillary lymph node metastases in
univariate analysis
Factor Adjusted odds ratio
(95% confidence interval)
P value
Age 0.95 (0.91-1.00) 0.049
Multicentric disease 1.46 (0.41-5.22) 0.561
Tumor size >2 cm 2.48 (0.81-7.59) 0.113
Vascular and lymphatic invasion 17.94 (4.78-67.30) <0.001
Epithelial hyperplasia 1.73 (0.52-5.77) 0.373
Necrosis 0.49 (0.13-1.84) 0.292
In situ carcinoma 1.70 (0.42-6.84) 0.455
Perineural invasion 1.13 (0.31-4.20) 0.853
CK5 positivity 0.003 (0.000-0.23) 0.009
CK14 positivity 5.22 (0.19-140.76) 0.326
EGFR positivity 3.94 (0.55-28.17) 0.171
Basal-like tumor 3.85 (0.18-83.02) 0.389
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existing prognostic markers do not identify this group,
patients with basal-like and non-basal-like tumours are
currently treated similarly. In this study, when all
tumors were classified into five groups based on ER/PR/
HER2 and basal-cytokeratin expressions, ALNM rate
was lower in only basal-like phenotype. In addition, this
study identified lack of CK5 expression as an indepen-
dent predictor of ALNM, with tumors expressing CK5
bearing a significantly smaller risk (adjusted OR = 0.003,
95% CI 0.000-0.23, p = 0.009).
Marked differences in the extent of lymph node invol-
vement, multicentric/multifocal disease, lymphovascular
invasion (LVI), and extensive intraductal component
were observed among subtypes. Only the basal subtype
was found to differ significantly from the luminal A sub-
type with regard to the risk of nodal metastasis. This
subtype was a significant predictor of having involve-
ment of four or more nodes on multivariate analysis.
However, some studies have shown in patients without
ALNM that expression of basal CK was associated with
a poor prognosis [15,49]. New prognostic markers are
quite important for this group of patients since the
prognosis for node-negativep a t i e n t si sl e s sc l e a r ,a n d
the clinical decision to give or withhold systemic therapy
is difficult, depending only on tumor size and grade.
CK5 expression appears to be a useful marker to define
the group of breast tumors with a poor prognosis even
in the absence of ALNM.
Mutations in the tumor suppressor gene, p53, are pre-
sent in 18-25% of primary breast carcinomas [50,51]. A
previous study found significant association between
anti-p53 antibodies and tumor size, histological grade,
and the number of axillary lymph nodes involved [52].
TN breast cancers more frequently show p53 nuclear
expression; therefore, are likely to harbour TP53 gene
mutations more frequently [53]. In this study, patient
with P53 expression were present in 49% HER2 subtype,
and in 41% basal-like phenotype. However, p53 expres-
sion did not emerge as a significant factor associated
with ALNM. Expression of p53 could provide informa-
tion concerning a poor outcome in triple-negative breast
cancer. There is no definite answer to optimal manage-
ment of triple-negative tumors at this moment. In such
cases, consideration might well be given to more aggres-
sive or alternative treatment.
Proliferative activity of tumour cells assessed by
immunohistochemical Ki-67 expression is one of several
prognostic indicators in breast cancer. Intriguingly, all
the studies [54-56] have shown a statistical correlation
with clinical outcome irrespective of cut-off points. Pre-
vious studies have reported significant associations
between high Ki-67 index and lymph node status [57].
In contrast, similar to the findings of this study, a recent
study have shown that Ki-67 did not appear to be a
helpful predictor [58].
In this study, univariate analysis identified significant
associations between ALNM and twelve factors: age,
multicentric disease, tumor size, vascular and lymphatic
invasion, epithelial hyperplasia, necrosis, in situ carci-
noma, perineural invasion, basal-like phenotype, and
CK5, CK14 and EGFR expressions. However, only age,
CK5 expression and lymphatic/vascular invasion
remained to be significant predictors on multivariate
analysis. Increasing age and CK5 expression was asso-
ciated with decreased risk whereas lymphatic and vascu-
lar invasion was associated with an increased risk.
Clinical assessment of the axilla, tumor palpability and
the method of detection were not uniformly documen-
ted in our data set, thus were not included in the analy-
sis. This represents a limitation of this study. Another
potential weakness of this report may be that ALN sta-
tus we based on the results from a mixture of complete
axillary node dissection and sentinel lymph node proce-
dure. However, it has previously been shown that pre-
dictors for ALN status are independent of how the
lymph node resection was performed although the
metastatic detection rate in lymph nodes may be higher
using the sentinel node procedure since higher number
of metastases has been detected thorough histological
examination of the sentinel lymph node biopsies [59]. In
general, patients can be selected for breast-conserving
surgery with a high degree of accuracy by history, physi-
cal examination, and diagnostic mammography [60].
This study identified age, CK5 expression and vascular/
lymphatic invasion as three variables associated with
high-risk for ALNM. The latter two can be identified
preoperatively with reasonable accuracy by pathologic
evaluation of core needle biopsies [61]. As a result,
pathologists can accurately assess the true malignant
potential of IDCs by seeking lymph-vessel tumor emboli
as part of a histological prognostic classification. In
addition, patients with basal-like carcinomas may be less
sensitive to standard adjuvant chemotherapy than with
other types; necessitating novel therapeutic approaches.
Conclusion
In conclusion, findings of this study suggest that the
inclusion of biomarker profiles to predict nodal status at
diagnosis may provide additional information that has
the potential to be useful for decisions regarding breast-
conserving therapy, axillary surgery, and locoregional
radiation.
List of abbreviations
ALNM: Axillary lymph node metastasis; ALND: Axillary lymph node dissection;
ALN: Axillary lymph node; CK: Cytokeratin; IHC: Immunhistochemistry; HR:
Hormone Receptor; TN: Triple Negative; ER: Estrogen Receptor; PR:
Yenidunya et al. Diagnostic Pathology 2011, 6:18
http://www.diagnosticpathology.org/content/6/1/18
Page 7 of 9Progesterone Receptor; BLBC: Basal-like Breast Cancer; LN: Lymph Node;
SLNB: Sentinel Lymph Node Biopsy; CI: Confidence Intervals; EIC: Extensive
Intraductal Component; IDC: Invasive Ductal Carcinoma; LVI: Lymphovascular
Invasion; DFS: Disease Free Survival.
Authors’ contributions
SY carried out the data collection, the pathological and IHC evaluation and
interpretation, drafting and wrote the final manuscript; RB and HH
participated in pathological and IHC evaluation and interpretation. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 February 2011 Accepted: 13 March 2011
Published: 13 March 2011
References
1. Rosen PP, Groshen S, Kinne DW, Norton L: Factors influencing prognosis
in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0
patients with long-term follow-up. J Clin Oncol 1993, 11:2090-100.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA
Cancer J Clin 2001, 51:15-36.
3. Mettlin C: Global breast cancer mortality statistics. CA Cancer J Clin 1999,
49:138-44.
4. Fisher ER, Costantino J, Fisher B, Redmond C: Pathologic findings from the
National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for
15-year survival. National Surgical Adjuvant Breast and Bowel Project
Investigators. Cancer 1993, 71:2141-50.
5. Howat JM, Barnes DM, Harris M, Swindell R: The association of cytosol
oestrogen and progesterone receptors with histological features of
breast cancer and early recurrence of disease. Br J Cancer 1983,
47:629-40.
6. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP,
Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES:
Molecular classification of cancer: class discovery and class prediction by
gene expression monitoring. Science 1999, 286:531-7.
7. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C,
Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular
portraits of human breast tumours. Nature 2000, 406:747-52.
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T,
Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC,
Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene
expression patterns of breast carcinomas distinguish tumor subclasses
with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-74.
9. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-
Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM,
Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical
characterization of the basal-like subtype of invasive breast carcinoma.
Clin Cancer Res 2004, 10:5367-74.
10. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE,
Brown PO, Borresen-Dale AL, Botstein D: Repeated observation of breast
tumor subtypes in independent gene expression data sets. Proc Natl
Acad Sci USA 2003, 100:8418-23.
11. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P,
Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based
on gene expression profiles from a population-based study. Proc Natl
Acad Sci USA 2003, 100:10393-8.
12. Nagle RB, Bocker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, Jarasch ED:
Characterization of breast carcinomas by two monoclonal antibodies
distinguishing myoepithelial from luminal epithelial cells. J Histochem
Cytochem 1986, 34:869-81.
13. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF,
Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in
human breast carcinoma. J Pathol 2004, 203:661-71.
14. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH,
Robertson JF, Ellis IO: Morphological and immunophenotypic analysis of
breast carcinomas with basal and myoepithelial differentiation. J Pathol
2006, 208:495-506.
15. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J,
Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R,
Ross D, Botstein D, Brown P: Expression of cytokeratins 17 and 5
identifies a group of breast carcinomas with poor clinical outcome. Am J
Pathol 2002, 161:1991-6.
16. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R:
Prognostic relevance of basal cytokeratin expression in operable breast
cancer. Oncology 2005, 69:478-85.
17. Malzahn K, Mitze M, Thoenes M, Moll R: Biological and prognostic
significance of stratified epithelial cytokeratins in infiltrating ductal
breast carcinomas. Virchows Arch 1998, 433:119-29.
18. Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early-
stage breast cancer. Oncologist 2004, 9:606-16.
19. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP:
Management and survival of female breast cancer: results of a national
survey by the American College of Surgeons. Cancer 1980, 45:2917-24.
20. Ernst MF, Voogd AC, Balder W, Klinkenbijl JH, Roukema JA: Early and late
morbidity associated with axillary levels I-III dissection in breast cancer. J
Surg Oncol 2002, 79:151-5.
21. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM,
Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M,
Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ:
Randomized multicenter trial of sentinel node biopsy versus standard
axillary treatment in operable breast cancer: the ALMANAC. Trial J Natl
Cancer Inst 2006, 98:599-609.
22. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL,
Hayes DF, Kleer C, O’Malley FP, Page DL, Smith BL, Tan LK, Weaver DL,
Winer E: Protocol for the examination of specimens from patients with
invasive carcinoma of the breast. Arch Pathol Lab Med 2009, 133:1515-38.
23. Ellis IO, Elston CW: Histologic grade. In Breast Pathology. Edited by:
O’Malley FP, Pinder SE. Philadelphia, PA: Elsevier; 2006:225-33.
24. Jones C, Ford E, Gillett C, Ryder K, Merrett S, Reis-Filho JS, Fulford LG,
Hanby A, Lakhani SR: Molecular cytogenetic identification of subgroups
of grade III invasive ductal breast carcinomas with different clinical
outcomes. Clin Cancer Res 2004, 10:5988-97.
25. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P,
Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C,
Thurlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A,
Gusterson BA, Coates AS: Prognostic and predictive value of centrally
reviewed expression of estrogen and progesterone receptors in a
randomized trial comparing letrozole and tamoxifen adjuvant therapy
for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007,
25:3846-52.
26. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ,
Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S,
Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R,
Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of
Clinical Oncology/College of American Pathologists guideline
recommendations for human epidermal growth factor receptor 2
testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
27. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF,
Blamey RW, Macmillan D, Ellis IO: Basal phenotype identifies a poor
prognostic subgroup of breast cancer of clinical importance. Eur J Cancer
2006, 42:3149-56.
28. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G,
Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC,
Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer
subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006,
295:2492-502.
29. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status,
and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-7.
30. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ:
Meeting highlights: international expert consensus on the primary
therapy of early breast cancer 2005. Ann Oncol 2005, 16:1569-83.
31. Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, Sandrucci S,
Baltas B, Bussolati G: Meta-analysis of non-sentinel node metastases
associated with micrometastatic sentinel nodes in breast cancer. Br J
Surg 2004, 91:1245-52.
32. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G,
Pruneri G, Luini A, Intra M, Veronesi P, Galimberti V, Torrisi R, Cardillo A,
Goldhirsch A, Viale G: Size of breast cancer metastases in axillary lymph
Yenidunya et al. Diagnostic Pathology 2011, 6:18
http://www.diagnosticpathology.org/content/6/1/18
Page 8 of 9nodes: clinical relevance of minimal lymph node involvement. J Clin
Oncol 2005, 23:1379-89.
33. Silverstein MJ, Skinner KA, Lomis TJ: Predicting axillary nodal positivity in
2282 patients with breast carcinoma. World J Surg 2001, 25:767-72.
34. Kambouris AA: Axillary node metastases in relation to size and location
of breast cancers: analysis of 147 patients. Am Surg 1996, 62:519-24.
35. Fein DA, Fowble BL, Hanlon AL, Hooks MA, Hoffman JP, Sigurdson ER,
Jardines LA, Eisenberg BL: Identification of women with T1-T2 breast
cancer at low risk of positive axillary nodes. J Surg Oncol 1997, 65:34-9.
36. Lee JH, Kim SH, Suh YJ, Shim BY, Kim HK: Predictors of axillary lymph
node metastases (ALNM) in a Korean population with T1-2 breast
carcinoma: triple negative breast cancer has a high incidence of ALNM
irrespective of the tumor size. Cancer Res Treat 2010, 42:30-6.
37. Andea AA, Wallis T, Newman LA, Bouwman D, Dey J, Visscher DW:
Pathologic analysis of tumor size and lymph node status in multifocal/
multicentric breast carcinoma. Cancer 2002, 94:1383-90.
38. Coombs NJ, Boyages J: Multifocal and multicentric breast cancer: does
each focus matter? J Clin Oncol 2005, 23:7497-502.
39. Hasebe T, Okada N, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T,
Sasajima Y, Tsuda H, Kinoshita T: Grading system for lymph vessel tumor
emboli: significant outcome predictor for invasive ductal carcinoma of
the breast. Hum Pathol 2010, 41:706-15.
40. Hasebe T, Tamura N, Iwasaki M, Okada N, Akashi-Tanaka S, Hojo T,
Shimizu C, Adachi M, Fujiwara Y, Shibata T, Sasajima Y, Tsuda H, Kinoshita T:
Grading system for lymph vessel tumor emboli: significant outcome
predictor for patients with invasive ductal carcinoma of the breast who
received neoadjuvant therapy. Mod Pathol 2010, 23:581-92.
41. Park BW, Kim SI, Kim EK, Yang WI, Lee KS: Impact of patient age on the
outcome of primary breast carcinoma. J Surg Oncol 2002, 80:12-8.
42. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB,
Shamseddine AI: Effects of young age at presentation on survival in
breast cancer. BMC Cancer 2006, 6:194.
43. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R,
Viale G, Pruneri G, Veronesi P, Luini A, Intra M, Cardillo A, Torrisi R, Rocca A,
Goldhirsch A: Role of endocrine responsiveness and adjuvant therapy in
very young women (below 35 years) with operable breast cancer and
node negative disease. Ann Oncol 2006, 17:1497-503.
44. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP:
Predictive factors associated with axillary lymph node metastases in T1a
and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll
Surg 2000, 191:1-6.
45. Maibenco DC, Weiss LK, Pawlish KS, Severson RK: Axillary lymph node
metastases associated with small invasive breast carcinomas. Cancer
1999, 85:1530-6.
46. Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, Orel S,
Glick JH: The influence of young age on outcome in early stage breast
cancer. Int J Radiat Oncol Biol Phys 1994, 30:23-33.
47. Dairkee SH, Mayall BH, Smith HS, Hackett AJ: Monoclonal marker that
predicts early recurrence of breast cancer. Lancet 1987, 1:514.
48. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR,
Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA: The
prognostic implication of the basal-like (cyclin E high/p27 low/p53
+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related
breast cancer. Cancer Res 2004, 64:830-5.
49. Liu ZB, Wu J, Ping B, Feng LQ, Di GH, Lu JS, Shen KW, Shen ZZ, Shaol ZM:
Basal cytokeratin expression in relation to immunohistochemical and
clinical characterization in breast cancer patients with triple negative
phenotype. Tumori 2009, 95:53-62.
50. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J: Heterogeneity in
the clinical phenotype of TP53 mutations in breast cancer patients. Clin
Cancer Res 2000, 6:3923-31.
51. Pharoah PD, Day NE, Caldas C: Somatic mutations in the p53 gene and
prognosis in breast cancer: a meta-analysis. Br J Cancer 1999, 80:1968-73.
52. Kulic A, Sirotkovic-Skerlev M, Jelisavac-Cosic S, Herceg D, Kovac Z,
Vrbanec D: Anti-p53 antibodies in serum: relationship to tumor biology
and prognosis of breast cancer patients. Med Oncol 2010, 27:887-93.
53. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS:
Triple negative breast cancer: molecular profiling and prognostic impact
in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008,
111:27-44.
54. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P,
Eber M, Ghnassia JP: Comparative value of tumour grade, hormonal
receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive
markers in breast cancer patients treated with neoadjuvant
anthracycline-based chemotherapy. Eur J Cancer 2004, 40:205-11.
55. Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR: Hormone
receptors and proliferation in breast carcinomas of equivalent histologic
grades in pre- and postmenopausal women. Int J Cancer 2002, 98:118-27.
56. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S,
Iwase H: Coexistence of HER2 over-expression and p53 protein
accumulation is a strong prognostic molecular marker in breast cancer.
Breast Cancer Res 2004, 6:R24-30.
57. Wrba F, Chott A, Reiner A, Reiner G, Markis-Ritzinger E, Holzner JH: Ki-67
immunoreactivity in breast carcinomas in relation to transferrin receptor
expression, estrogen receptor status and morphological criteria. An
immunohistochemical study Oncology 1989, 46:255-9.
58. Kwon Y, Ro J, Kang HS, Kim SK, Hong EK, Khang SK, Gong G, Ro JY:
Clinicopathological parameters and biological markers predicting non-
sentinel node metastasis in sentinel node-positive breast cancer
patients. Oncol Rep 2011.
59. Viale G, Zurrida S, Maiorano E, Mazzarol G, Pruneri G, Paganelli G,
Maisonneuve P, Veronesi U: Predicting the status of axillary sentinel
lymph nodes in 4351 patients with invasive breast carcinoma treated in
a single institution. Cancer 2005, 103:492-500.
60. Morrow M, Schmidt R, Hassett C: Patient selection for breast conservation
therapy with magnification mammography. Surgery 1995, 118:621-6.
61. Jacobs TW, Siziopikou KP, Prioleau JE, Raza S, Baum JK, Hayes DF, Schnitt SJ:
Do prognostic marker studies on core needle biopsy specimens of
breast carcinoma accurately reflect the marker status of the tumor? Mod
Pathol 1998, 11:259-64.
doi:10.1186/1746-1596-6-18
Cite this article as: Yenidunya et al.: Predictive value of pathological and
immunohistochemical parameters for axillary lymph node metastasis in
breast carcinoma. Diagnostic Pathology 2011 6:18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yenidunya et al. Diagnostic Pathology 2011, 6:18
http://www.diagnosticpathology.org/content/6/1/18
Page 9 of 9